Tarlatamab (IMDYLLTRA, Amgen) is indicated for 'the treatment of adult patients with extensive-stage small-cell lung cancer (ES‑SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy'.
The dosage schedule is available in the summary of product characteristics for tarlatamab.
The list price of tarlatamab is £955 per 1‑mg vial or £9,550 per 10‑mg vial (excluding VAT; company submission). The company has a commercial arrangement, which would have applied if tarlatamab had been recommended.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Amgen's Carbon Reduction Plan template (PDF).